ICER's evaluation of Vertex Pharmaceuticals' non-opioid pain drug, Journavx, finds cost-effectiveness related to potential ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $478.12, a high ...

Despite a $400 million impairment charge, analysts say the removal of a drug-device combo from its portfolio is not a huge ...

We recently published a list of Jim Cramer Looked At These 23 Stocks Recently. In this article, we are going to take a look ...